Aardvark Therapeutics, Inc. (AARD)
AARD moved a median of -0.91% 30 minutes after news, and 0.00% by the close. How AARD actually reacts to news — the realized, point-in-time move the market made, measured across 514 labeled events over the last three years with zero look-ahead.
AARD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 468 |
| 30-min | -0.91% | 41% | 494 |
| 60-min | -1.12% | 37% | 494 |
| to close | 0.00% | 49% | 494 |
| Middle 50% of AARD reactions | -1.77% to +1.61% |
|---|---|
| Median reaction (30-min) | -0.91% |
| Measured reactions | 514 |
Half of all Aardvark Therapeutics, Inc. news events land between -1.77% and +1.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AARD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 18 | -5.96% | 33% | -8.53% |
| Coverage initiations | 35 | -2.75% | 17% | -5.87% |
| Rating reiterations | 34 | +0.23% | 53% | -2.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AARD ranks against every other measured name →
That’s how AARD usually reacts — get an email when it moves on news →Email me when AARD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AARD's baseline. Nothing else.
Recent AARD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on | Press release | GlobeNewswire | +2.46% | +0.00% | |
| Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is In | Press release | GlobeNewswire | -2.19% | -5.37% | |
| Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD | Press release | PR Newswire | -1.25% | -7.48% | |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | -1.25% | -7.48% | |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Press release | GlobeNewswire | +2.62% | -1.26% | |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your | Press release | GlobeNewswire | +2.62% | -1.26% | |
| Form 8-K Aardvark Therapeutics, For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | +3.25% | |
| Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Of | Press release | GlobeNewswire | — | -0.59% | |
| Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +4.57% | +3.78% | |
| Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigati | Press release | GlobeNewswire | +0.00% | +4.36% | |
| Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws | Press release | GlobeNewswire | — | +1.70% | |
| Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | +0.00% | +2.18% | |
| LAWSUIT ALERT: Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) shares should contact the Shareholders Foundation | Press release | ACCESS Newswire | +0.76% | -8.06% | |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | -3.70% | +2.88% | |
| Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately | Press release | PR Newswire | — | +0.08% | |
| Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and The Simply Good Foods Company (NASDAQ: SMPL); Grabar Law Office is Investigating Claims on Your Beha | Press release | GlobeNewswire | -6.33% | +7.02% | |
| Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately | Press release | PR Newswire | -6.33% | +7.02% | |
| Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your Behalf | Press release | GlobeNewswire | +0.29% | -3.92% | |
| Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit | Press release | Business Wire | -6.48% | +4.47% | |
| Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately | Press release | PR Newswire | -6.48% | +4.47% | |
| Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately | Press release | GlobeNewswire | — | +2.23% | |
| Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD | Press release | Business Wire | +4.99% | +15.40% | |
| LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation | Press release | PR Newswire | +0.00% | -2.16% | |
| Form 8-K Aardvark Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.83% | -9.37% | |
| Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -2.10% | -8.11% | |
| Form 10-Q Aardvark Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.10% | -8.11% | |
| Form 8-K Aardvark Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -2.10% | -8.11% | |
| Form ARS Aardvark Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.14% | -18.91% | |
| Form DEF 14A Aardvark Therapeutics, For: Aug 14 | SEC filing · Form DEF | SEC EDGAR | -0.14% | -18.91% | |
| Form PRE 14A Aardvark Therapeutics, For: Aug 14 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +11.85% | |
| Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS | Press release | PR Newswire | -1.19% | +0.20% | |
| Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS | Press release | PR Newswire | +0.20% | +3.03% | |
| Form 8-K Aardvark Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | -1.54% | |
| Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS | Press release | PR Newswire | +1.27% | +6.87% | |
| Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS | Press release | PR Newswire | -2.79% | +4.88% | |
| Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold | Press release | GlobeNewswire | +10.39% | +5.54% | |
| Form 8-K Aardvark Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +10.39% | +5.54% | |
| Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -5.83% | -2.78% | |
| Form 10-Q Aardvark Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +3.24% | |
| Form 8-K Aardvark Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -5.83% | -2.78% | |
| Form EFFECT Aardvark Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.86% | -3.95% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.86% | -3.95% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.86% | -3.95% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +7.92% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.55% | +0.28% | |
| Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.14% | +1.43% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.00% | -5.35% | |
| Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -2.25% | -0.13% | |
| Form 8-K Aardvark Therapeutics, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -3.25% | -5.75% | |
| Form S-8 Aardvark Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.25% | -5.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AARD section they belong to.
Where else AARD is measured.
AARD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aardvark Therapeutics, Inc.'s median reaction calculated?
Every labeled AARD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 514 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of AARD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AARD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.